• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chemotherapy Research and Practice >Neoadjuvant Chemoradiation in Squamous Cell Carcinoma of the Maxillary Sinus: A 26-Year Experience
【24h】

Neoadjuvant Chemoradiation in Squamous Cell Carcinoma of the Maxillary Sinus: A 26-Year Experience

机译：上颌窦鳞状细胞癌的新辅助化学放疗：26年的经验。

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background. The aim of our study was to evaluate the effects of neoadjuvant platinum-based radiochemotherapy (RCT) in patients with maxillary sinus squamous cell carcinoma and to compare the results with other multimodality treatment concepts for advanced-stage maxillary sinus carcinoma in the literature.Methods. In total, 53 patients with squamous cell carcinoma of the maxillary sinus were reviewed retrospectively. All patients received a neoadjuvant RCT containing either cisplatin or carboplatin followed by radical surgery. Overall survival and locoregional control were plotted by Kaplan-Meier analysis. Prognostic factors were identified through univariate and multivariate analysis.Results. Five-year overall survival for all patients was 35%. Eleven patients achieved a complete response after radiochemotherapy. The complete response rate was significantly higher for patients treated with cisplatin (P=0.028); however the 5-year overall survival rates did not differ significantly (P=0.673) for patients treated with cisplatin (37%) and carboplatin (32%). Orbital invasion (P=0.005) and complete response to radiochemotherapy (P=0.021) had a significant impact on overall survival in univariate analysis.Conclusions. Neoadjuvant radiochemotherapy followed by radical surgery is an effective treatment for patients with advanced maxillary sinus squamous cell carcinoma. In terms of treatment response cisplatin seems to be more effective than carboplatin.
机译：背景。我们的研究目的是评估新辅助铂基放射化学疗法（RCT）在上颌窦鳞状细胞癌患者中的疗效，并将该结果与晚期上颌窦癌的其他多模态治疗方案进行比较。回顾性分析53例上颌窦鳞状细胞癌患者的临床资料。所有患者均接受包含顺铂或卡铂的新辅助RCT，然后进行根治性手术。通过Kaplan-Meier分析绘制总体存活率和局部区域控制。通过单因素和多因素分析确定预后因素。所有患者的五年总生存率为35％。放化疗后有11名患者完全缓解。顺铂治疗的患者的完全缓解率明显更高（P = 0.028）;然而，接受顺铂（37％）和卡铂（32％）治疗的患者的5年总生存率没有显着差异（P = 0.673）。在单因素分析中，眼眶侵犯（P = 0.005）和对放化疗的完全反应（P = 0.021）对总体生存有重要影响。新辅助放化疗联合根治性手术是晚期上颌窦鳞状细胞癌患者的有效治疗方法。就治疗反应而言，顺铂似乎比卡铂更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号